AxoGen, Inc.
HealthcareNASDAQ:AXGN · NASDAQ Capital Market
+$0.64 today
Vol 1.34M · Avg 1.01M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-12.2%
avg -41.3%
ROIC
-3.9%
avg -14.8%
ROA
-7.1%
avg -16.3%
Analysis
ROIC is currently the strongest return metric at -3.9% versus its period average of -14.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael D. Dale | President, Chief Executive Officer & Director | $1.70M | — | 66 | $98,000.00 | 0.18% |
Marc A. Began | Executive VP, General Counsel, Secretary & Chief Compliance Officer | $772,680.00 | — | 58 | $11,250.00 | 0.02% |
Jens Schroeder Kemp | Chief Marketing Officer | $696,506.00 | — | 49 | $72,451.00 | 0.14% |
Erick DeVinney | Chief Innovation Officer | $679,041.00 | — | 50 | $6,363.00 | 0.01% |
Lindsey Hartley | Chief Financial Officer | $632,806.00 | — | — | $65,719.00 | 0.12% |
Craig A. Swandal | Vice President of Operations | $406,018.00 | — | 65 | $25,108.00 | 0.05% |
Ivica Ducic | Chief Medical Officer | — | — | — | — | — |
Harold D. Tamayo | Vice President of Finance & Investor Relations | — | — | — | $30,476.00 | 0.06% |
Doris Quackenbush | Vice President of Sales | — | — | — | $92,416.00 | 0.17% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
44
$15.24M
Net Sentiment
$15.24M
Net selling
Most Active
Burke William P. Mr.
13 transactions
1–10 of 44
Analysis
Insiders reported 0 buys worth $0.00 and 44 sells worth $15.24M over the last 12 months. That adds up to net selling of $15.24M. Burke William P. Mr. was the most active insider with 13 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +52.6% | +22.2% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +52.6% over three years. Forward estimates point to Revenue at +22.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Taysha Gene Therapies, Inc.
NASDAQ:TSHA
$1.64B
Integra LifeSciences Holdings Corporation
NASDAQ:IART
$1.38B
AdaptHealth Corp.
NASDAQ:AHCO
$1.38B
IRadimed Corporation
NASDAQ:IRMD
$1.20B
Tandem Diabetes Care, Inc.
NASDAQ:TNDM
$1.14B
OPKO Health, Inc.
NASDAQ:OPK
$1.07B
InMode Ltd.
NASDAQ:INMD
$817.88M
Sana Biotechnology, Inc.
NASDAQ:SANA
$745.82M
Claritev Corporation
NYSE:CTEV
$526.61M
LifeMD, Inc.
NASDAQ:LFMD
$227.30M
Who manages AXGN?
AxoGen, Inc. (AXGN) lists 9 active executives. The top listed executive is Lindsey Hartley, Chief Financial Officer.
Are AXGN insiders buying or selling?
Recent insider activity shows net selling of $20.47M.
Explore More
Continue the stock analysis
Jump to another research area for this company.